Murine models of Vpr-mediated pathogenesis

Current HIV Research

Volumn 7, Issue 2, 2009, Pages 129-135

  Snyder, Alexandra ^a   Ross, Michael J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cell cycle; HIV 1; HIV associated nephropathy; Immune response; Vpr

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; RECOMBINANT PROTEIN; RECOMBINANT VPR PROTEIN; UNCLASSIFIED DRUG; VPR PROTEIN; VIRULENCE FACTOR; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CARDIOMYOPATHY; CELL CYCLE ARREST; CELL CYCLE REGULATION; DEMENTIA; DRUG PROTEIN BINDING; EXPERIMENTAL MOUSE; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STAPHYLOCOCCUS INFECTION; TISSUE DISTRIBUTION; VIRUS PATHOGENESIS; ANIMAL; ANIMAL MODEL; CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

ANIMALS; CELL LINE; HIV INFECTIONS; HIV-1; MICE; MODELS, ANIMAL; VIRULENCE FACTORS; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 64749104732     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209787581526     Document Type: Review

References (53)

1. Le Rouzic E, Benichou S. The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2005; 2: 11.
2. Bolton DL, Lenardo MJ. Vpr cytopathicity independent of G2/M cell cycle arrest in human immunodeficiency virus type 1-infected CD4+ T cells. J Virol 2007; 81: 8878-90.
3. Heinzinger NK, Bukinsky MI, Haggerty SA, et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91: 7311-5.
4. Levy DN, Refaeli Y, MacGregor RR, Weiner DB. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994; 91: 10873-7.
5. Ayyavoo V, Muthumani K, Kudchodkar S, et al. HIV-1 viral protein R compromises cellular immune function in vivo. Int Immunol 2002; 14: 13-22.
6. Zimmerman ES, Chen J, Andersen JL, et al. Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol. 2004; 24: 9286-94.
7. Azuma A, Matsuo A, Suzuki T, Kurosawa T, Zhang X, Aida Y. Human immunodeficiency virus type 1 Vpr induces cell cycle arrest at the G(1) phase and apoptosis via disruption of mitochondrial function in rodent cells. Microbes Infect 2006; 8(3): 670-9.
8. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 2007; 4: 57.
9. Hrecka K, Gierszewska M, Srivastava S, et al. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci USA 2007; 104: 11778-83.
10. Tan L, Ehrlich E, Yu XF. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol 2007; 81: 10822-30.
11. Dehart JL, Planelles V. Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation. J Virol 2008; 82: 1066-2.
12. Chang LJ, Chen CH, Urlacher V, Lee TZ. Differential apoptosis effects of primate lentiviral Vpr and Vpx in mammalian cells. J Biomed Sci 2000; 7: 322-33.
13. Muthumani K, Choo AY, Zong WX, et al. The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol 2006; 8: 170-9.
14. Jones GJ, Barsby NL, Cohen EA, et al. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 2007; 27: 3703-11.
15. Muthumani K, Choo AY, Hwang DS, et al. HIV-1 Viral protein-r (Vpr) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo. Mol Ther 2005; 12: 910-21.
16. McCray AN, Ugen KE, Heller R. Enhancement of anti-melanoma activity of a plasmid expressing HIV-1 Vpr delivered through in vivo electroporation. Cancer Biol Ther 2007; 6: 1269-75.
17. Borgne-Sanchez A, Dupont S, Langonne A, et al. Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells. Cell Death Differ 2007; 14: 422-35.
18. Eckstein DA, Sherman MP, Penn ML, et al. HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med 2001; 194: 1407-19.
19. Andersen JL, Zimmerman ES, DeHart JL, et al. ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis. Cell Death Differ 2005; 12: 326-34.
20. Zimmerman ES, Sherman MP, Blackett JL, et al. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol 2006; 80: 10407-18.
21. Yasuda J, Miyao T, Kamata M, Aida Y, Iwakura Y. T cell apoptosis causes peripheral T cell depletion in mice transgenic for the HIV-1 vpr gene. Virology 2001; 285: 181-92.
22. Muthumani K, Hwang DS, Dayes NS, Kim JJ, Weiner DB. The HIV-1 accessory gene vpr can inhibit antigen-specific immune function. DNA Cell Biol 2002; 21: 689-95.
23. Muthumani K, Bagarazzi M, Conway D, et al. Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J Med Primatol 2002; 31: 179-85.
24. Muthumani K, Kudchodkar S, Zhang D, et al. Issues for improving multiplasmid DNA vaccines for HIV-1. Vaccine 2002; 20: 1999-2003.
25. Ayyavoo V, Mahboubi A, Mahalingam S, et al. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med 1997; 3: 1117-23.
26. Muthumani K, Hwang DS, Choo AY, et al. HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol 2005; 17: 103-16.
27. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004; 157: 3-10.
28. Amini S, Khalili K, Sawaya BE. Effect of HIV-1 Vpr on cell cycle regulators. DNA Cell Biol 2004; 23: 249-260.
29. Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD. Localization of HIV-1 in human brain using polymerase chain reaction/ in situ hybridization and immunocytochemistry. Ann Neurol 1996; 39: 705-11.
30. Thompson KA, Churchill MJ, Gorry PR, et al. Astrocyte specific viral strains in HIV dementia. Ann Neurol 2004; 56: 873-7.
31. Wheeler ED, Achim CL, Ayyavoo V. Immunodetection of human immunodeficiency virus type 1 (HIV-1) Vpr in brain tissue of HIV-1 encephalitic patients. J Neurovirol 2006; 12: 200-10.
32. Huang MB, Weeks O, Zhao LJ, Saltarelli M, Bond VC. Effects of extracellular human immunodeficiency virus type 1 vpr protein in primary rat cortical cell cultures. J Neurovirol 2000; 6: 202-20.
33. Sabbah EN, Roques BP. Critical implication of the (70-96) domain of human immunodeficiency virus type 1 Vpr protein in apoptosis of primary rat cortical and striatal neurons. J Neurovirol 2005; 11: 489-502.
34. Cheng X, Mukhtar M, Acheampong EA, et al. HIV-1 Vpr potently induces programmed cell death in the CNS in vivo. DNA Cell Biol 2007; 26: 116-31.
35. Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997; 100: 84-92.
36. Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11: 2079-87.
37. Husain M, Gusella GL, Klotman ME, et al. HIV-1 Nef Induces Proliferation and Anchorage-Independent Growth in Podocytes. J Am Soc Nephrol 2002; 13: 1806-15.
38. D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998; 18: 406-21.
39. D'Agati V, Suh JI, Carbone L, Cheng JT, Appel G. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int 1989; 35: 1358-70.
40. He JC, Husain M, Sunamoto M, et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 2004; 114: 643-51.
41. Husain M, D'Agati VD, He JC, Klotman ME, Klotman PE. HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. AIDS 2005; 19: 1975-80.
42. Dickie P, Roberts A, Uwiera R, Witmer J, Sharma K, Kopp JB. Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy. Virology 2004; 322: 69-81.
43. Zhong J, Zuo Y, Ma J, et al. Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int 2005; 68: 1048-60.
44. Zuo Y, Matsusaka T, Zhong J, et al. HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J Am Soc Nephrol 2006; 17: 2832-43.
45. Abbott KC, Hypolite I, Welch PG, Agodoa LY. Human immunodeficiency virus/ acquired immunodeficiency syndrome- associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001; 14: 377-83.
46. Lewis W, Miller YK, Haase CP, et al. HIV viral protein R causes atrial cardiomyocyte mitosis, mesenchymal tumor, dysrhythmia, and heart failure. Lab Invest 2005; 85: 182-92.
47. Kulkosky J, Laptev A, Shetty S, et al. Human immunodeficiency virus type 1 Vpr alters bone marrow cell function. Blood 1999; 93: 1906-15.
48. Andersen JL, Planelles V. The role of Vpr in HIV-1 pathogenesis. Curr HIV Res 2005; 3: 43-51.
49. Andersen JL, DeHart JL, Zimmerman ES, et al. HIV-1 Vprinduced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog 2006; 2: e127.
50. Rosenstiel P, Letourneau TGA, Chan J, et al. HIV-1 vpr Impairs Cytokinesis in Human Proximal Tubule Cells leading to Multinucleation and Hypertrophy: Implications for HIVAN Pathogenesis. Kidney Int 2008; (In Press).
51. Jacotot E, Ferri KF, El Hamel C, et al. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 2001; 193: 509-19.
52. Muthumani K, Choo AY, Premkumar A, et al. Human immunodeficiency virus type 1 (HIV-1) Vpr-regulated cell death: insights into mechanism. Cell Death Differ 2005; 12(Suppl 1): 962-70.
53. Moon HS, Yang JS. Role of HIV Vpr as a regulator of apoptosis and an effector on bystander cells. Mol Cells 2006; 21: 7-20.